Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post on LinkedIn:
“Our first-line investigator initiated clinical trial for stage IV microsatellite stable colorectal cancer using only immunotherapy (BOT/BAL, BBOpCo) is featured here by the Triangle Business Journal!
- MSS CRC is treated with sequential lines of chemotherapy, we are the only group to use immunotherapy alone in the first line metastatic setting.
- We have enrolled 15 patients in 14 months, twice as fast as we expected (This is the result I am most proud of, it tells me that we are speaking to patients directly with this approach)
- This study is funded by Gateway and internal support, we have done this for $40,000 per patient, which is about half the cost of most studies. Hopefully, we will obtain more funding to continue the study and expand.
- Data will be presented at AACR 2026 in April, and we are working on spatial biology and blood markers of response for later meetings.
There will be more coverage to come over the course of this month and next on BBOpCo!”
Quoting Duke Cancer Institute’s post:
“A clinical trial led by DCI members is testing a powerful new immunotherapy that unleashes the body’s own defenses to fight advanced colorectal cancer.”
Other articles featuring Nicholas DeVito and Duke Cancer Institute on OncoDaily.